Trial Profile
Ingenol Mebutate (Picato) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary) ; Methyl aminolevulinate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- 22 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 22 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 04 Apr 2018 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2018.